Bardia A et al. AMEERA-5: A randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Thera Adv Med Oncol 2022;14:17588359221083956. Abstract
Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine thearpy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/ki in metastatic setting. SABCS 2022;Abstract GS3-01.
Bardia A et al. Genomic profiling of premenopausal HR+ and HER2- metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine therapy and ribociclib. JCO Precis Oncol 2021;5:PO.20.00445. Abstract
Blum JL et al. Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer. Clin Can Res 2022;28(7):1383-90. Abstract
Fasching PA et al. Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2 negative, untreated early breast cancer (ER+/HER2- eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. ASCO 2022;Abstract 589.
Hamilton EP et al. ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer: Phase 1b cohort (Part C) of a phase 1/2 study. ASCO 2022;Abstract TPS1120.
Harbeck N et al. A look at current and potential treatment approaches for hormone receptor-positive, HER2-netagive early breast cancer. Cancer 2022;128S11:2209-23. Abstract
Howell SJ et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): Overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol 2022;23(7):851-64. Abstract
Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-postitive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401(10371):105-17. Abstract
Hurvitz SA et al. DESTINY-Changing results for advanced breast cancer. N Engl J Med 2022;387(1):75-6. Abstract
Hurvitz SA et al. Recent progress in antibody-drug conjugate therapy for cancer. Nat Cancer 2022;3(12):1412-3. Abstract
Jerusalem G et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis. Cancer Discov 2022;12(12):2754-62. Abstract
Lambertini M et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systemic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-90. Abstract
Meric-Bernstam F et al. Phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer. SABCS 2022;Abstract PD13-08.
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer: Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Moore HCF et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372(10):923-32. Abstract
Oktay K et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36(19):1994-2001. Abstract
Oliveira M et al. Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-Positive HER2-negative breast cancer: Results of the randomized, multi-dose Phse 2 SERENA-2 trial. SABCS 2022;Abstract GS3-02.
Schmid P et al. lidERA breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2-early breast cancer. SABCS 2022;Abstract OT-03-02.
Sparano JA et al. Trial assigning individualized options for treatment (TAILORx): An update including 12-year event rates. SABCS 2022;Abstract GS1-05.
Tung NM et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol 2021;39(26):2959-61. Abstract
Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III CAPItello-291 trial. SABCS 2022;Abstract GS3-04.
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1-2022.
Zhang S et al. Oncotype DX Recurrence Score in premenopausal women. Thera Adv Med Oncol 2022;14:17588359221081077. Abstract